Who is sponsoring NCT01833897?

NCT01833897 is sponsored by New York State Psychiatric Institute.

What condition does NCT01833897 study?

NCT01833897 studies Bipolar Disorder.

What drugs are being tested in NCT01833897?

Interventions: Standard of Care, Ketamine, D-cycloserine.

What is the status of NCT01833897?

NCT01833897 is currently COMPLETED.

Last reviewed 2016-04-25 · How we verify

NMDA Antagonists in Bipolar Depression

NCT01833897 Phase 4 COMPLETED Results posted

The purpose of this study is to test whether ketamine and D-cycloserine can be safely and effectively used for the treatment of depression. The investigators hypothesize that ketamine will serve as a rapid acting and safe antidepressant in patients with bipolar depression, and furthermore, that D-cycloserine will serve as an effective therapy following ketamine treatment.

Details

Lead sponsor	New York State Psychiatric Institute
Phase	Phase 4
Status	COMPLETED
Enrolment	8
Start date	2013-03
Completion	2016-03

Conditions

Bipolar Disorder

Interventions

Standard of Care
Ketamine
D-cycloserine

Primary outcomes

Hamilton Depression Rating Scale (HAM-D) — 8 weeks
Depression rating scale: Range 0-53, higher scores indicate worse depression. 0-7 = Normal 8-13 = Mild Depression 14-18 = Moderate Depression 19-22 = Severe Depression ≥ 23 = Very Severe Depression

Countries

United States